The Jackson Laboratory has disclosed short transient receptor potential channel 3 (TRPC3) and short transient receptor potential channel 6 (TRPC6) antagonists reported to be useful for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results